MRC1 and cancer: Unexpectedly, the cisplatin-treated p53−/− cancer cells also activated monocyte polarization into the M2 phenotype with CD206 increase (1.16-fold) while the Oligo-Fucoidan-treated p53−/− cells decreased the CD206 level (0.63-fold) compared to MOCK control (Figure 6C).